Sho Masayuki, Kishimoto Koji, Harada Hiroshi, Livak Mauren, Sanchez-Fueyo Alberto, Yamada Akira, Zheng Xin Xiao, Strom Terry B, Basadonna Giacomo P, Sayegh Mohamed H, Rothstein David M
Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13230-5. doi: 10.1073/pnas.0505070102. Epub 2005 Sep 6.
Peripheral tolerance can be achieved in many but not all murine allograft models. The requirements for controlling more aggressive immune responsiveness and generating peripheral tolerance in stringent allograft models are unknown. Understanding these requirements will provide insight toward ultimately achieving tolerance in humans, which are also resistant. We now demonstrate that the combination of donor-specific transfusion, anti-CD45RB, and anti-CD154 uniformly achieves >90-d survival of BALB/c skin allografts on C57BL/6 recipients. Recipients exhibit marked hyporesponsiveness to alloantigen in vitro. In distinct contrast to less rigorous models, engraftment remains absolutely dependent on cytotoxic T lymphocyte antigen 4 signaling, even after grafts are healed, suggesting that prolonged engraftment cannot simply be attributed to more effective depletion of alloreactive T cells but is actively maintained by regulation. Concordantly, we show that both CD4 and CD8 regulatory cells are required and can transfer donor-specific tolerance to naïve recipients. Nonetheless, most recipients ultimately develop gradual graft loss (median survival time = 140 d), suggesting that alloreactive cells emerging from the thymus eventually overwhelm regulatory capacity. In agreement, adding thymectomy to the regimen results in permanent engraftment (>250 d) and donor-specific tolerance not observed previously in this model. These results highlight the potency of both CD4 and CD8 regulatory cells but also suggest that in stringent settings, regulatory T cell longevity and capacity for infectious tolerance compete with prolonged graft immunogenicity and thymic output. These results provide insight into the mechanisms of tolerance in stringent models and provide a rational basis for innovative tolerogenic strategies in humans.
在许多但并非所有的小鼠同种异体移植模型中都能实现外周耐受。在严格的同种异体移植模型中,控制更强的免疫反应性并产生外周耐受的要求尚不清楚。了解这些要求将为最终在同样具有抗性的人类中实现耐受提供见解。我们现在证明,供体特异性输血、抗CD45RB和抗CD154的联合应用能使C57BL/6受体上的BALB/c皮肤同种异体移植的存活期一致地超过90天。受体在体外对同种异体抗原表现出明显的低反应性。与不太严格的模型形成鲜明对比的是,即使在移植物愈合后,植入仍然绝对依赖细胞毒性T淋巴细胞抗原4信号传导,这表明延长的植入不能简单地归因于对同种反应性T细胞更有效的清除,而是由调节作用积极维持的。与此一致,我们表明CD4和CD8调节性细胞都是必需的,并且可以将供体特异性耐受转移给未接触过抗原的受体。尽管如此,大多数受体最终会逐渐出现移植物丢失(中位存活时间 = 140天),这表明从胸腺中产生的同种反应性细胞最终会超过调节能力。同样,在方案中增加胸腺切除术会导致永久植入(>250天)和在此模型中以前未观察到的供体特异性耐受。这些结果突出了CD4和CD8调节性细胞的效力,但也表明在严格的情况下,调节性T细胞的寿命和感染耐受能力与延长的移植物免疫原性和胸腺输出相互竞争。这些结果为严格模型中的耐受机制提供了见解,并为人类创新的致耐受策略提供了合理依据。